

Raffaele Califano

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8431452/raffaele-califano-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42 papers	1,848 citations	19 h-index	42 g-index
50 ext. papers	2,591 ext. citations	6.4 avg, IF	4.43 L-index

#	Paper	IF	Citations
42	Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). <i>Journal of Clinical Oncology</i> , 2021 , 39, 619-630	2.2	68
41	Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 2091-2108	8.9	19
40	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3713-3736	4.4	0
39	CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. <i>European Journal of Cancer</i> , 2020 , 127, 160-172	7.5	69
38	Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020 , 9, 2696-2715	4.4	14
37	First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions. <i>Drugs</i> , 2020 , 80, 1783-1797	12.1	5
36	Immune checkpoint blockade in small cell lung cancer. <i>Lung Cancer</i> , 2019 , 137, 31-37	5.9	11
35	Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions. <i>OncoTargets and Therapy</i> , 2019 , 12, 7857-7864	4.4	25
34	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019 , 133, 163-166	5.3	19
33	First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light. <i>Lung Cancer</i> , 2019 , 134, 245-253	5.9	23
32	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019 , 135, 74-77	5.3	9
31	Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2019 , 129, 63-71	5.9	18
30	Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2019 , 106, 144-159	7.5	108
29	Current and future therapeutic approaches for the treatment of small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 473-486	3.5	22
28	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2018 , 19, 521-536	21.7	315
27	The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer. <i>Drugs and Aging</i> , 2018 , 35, 819-834	4.7	7
26	Treatment Resistant denovoEpidermal Growth Factor Receptor (EGFR)-mutated Small Cell Lung Cancer. <i>European Oncology and Haematology</i> , 2018 , 14, 84	0.1	2

25	Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios. <i>Journal of Thoracic Disease</i> , 2018 , 10, S1494-S1502	2.6	11
24	Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2017 , 111, 51-58	5.9	11
23	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. <i>Cell</i> , 2017 , 171, 1259-1271.e11	56.2	541
22	SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. <i>British Journal of Cancer</i> , 2017 , 117, 938-946	8.7	11
21	Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?. <i>ESMO Open</i> , 2016 , 1, e000022	6	13
20	Therapies in the pipeline for small-cell lung cancer. <i>British Medical Bulletin</i> , 2016 , 119, 37-48	5.4	8
19	Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 176-87	5.4	22
18	Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. <i>Future Oncology</i> , 2016 , 12, 551-64	3.6	7
17	Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?. <i>Drugs</i> , 2016 , 76, 831-40	12.1	11
16	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2016 , 18, 59	6.3	28
15	Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. <i>Cancer Treatment Reviews</i> , 2015 , 41, 401-11	14.4	33
14	Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. <i>Clinical Lung Cancer</i> , 2015 , 16, e223-8	4.9	30
13	Aromatase Inhibitors: A New Reality for the Adjuvant Endocrine Treatment of Early-Stage Breast Cancer in Postmenopausal Women 2014 , 99-130		
12	Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 1582-90	4.3	107
11	Management of small cell lung cancer: recent developments for optimal care. <i>Drugs</i> , 2012 , 72, 471-90	12.1	52
10	Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial. <i>Lung Cancer</i> , 2012 , 76, 72-7	5.9	23
9	Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. <i>Drugs</i> , 2012 , 72 Suppl 1, 28-36	12.1	54
8	Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation. <i>Drugs</i> , 2012 , 72 Suppl 1, 3-10	12.1	5

7	Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. <i>Lung Cancer</i> , 2011 , 72, 378-83	5.9	46
6	Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. <i>Lung Cancer</i> , 2011 , 73, 338-44	5.9	4
5	Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. <i>Lung Cancer</i> , 2011 , 74, 75-9	5.9	14
4	Targeted therapies in small cell lung cancer: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2010 , 2, 25-37	5.4	36
3	Lung cancer after treatment for breast cancer. <i>Lancet Oncology</i> , 2010 , 11, 1184-92	21.7	25
2	EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. <i>Targeted Oncology</i> , 2008 , 3, 173-186	5	3
1	Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 3265-75	4	10